Mr. Jiang is a founding partner and CEO of Shanghai Yafo Capital and Co-CEO of Cukierman-Yafo Investment. He has over 15 years Wall Street experience in investment banking, M&A, and investment of in both Israeli and American technology companies. He has worked with US and China investment banks. He was the Chinese General Manager of ISI Group (NY) and Managing Director of ISI research. Before that, he was a senior research analyst at Roth Capital (LA) where he was involved in multiple cross-border transactions. When at Xiangcai Securities, a leading investment bank in Shanghai, Sean was the executive director, responsible for advising foreign institutional investors in China’s stock markets.
Mr. Jiang is now a visiting professor at Concordia University (Wisconsin). He received his MBA from Pepperdine University, MA in finance from Fudan University, and BA in Economics from Central South University of China. He is a CFA Charter holder.
Mr. Tao is a Managing Partner of Yafo Capital and the Head of our U.S. Business. Mr. Tao has more than 15 years experience as an analyst and consultant working with public and private companies in North America and China across a variety of technology sectors. He has extensive knowledge on market analysis, business development, due diligence, and operations for U.S. – China cross-border transactions. He previously worked at William O’neil + Co. where he developed its Chinese operations and oversaw Chinese research. Before that, he was Director of Chinese research and senior research analyst at Roth Capital Partners where he supported over $2 billion cross-border equity financings.
Mr. Tao is a CFA Charter holder and has a MBA from University of California, Riverside.
Mr. Zheng is the Managing Director of Yafo Capital. He has been focusing on cross-border investment in healthcare sector since the beginning of his career life. Mr. Zheng has been involved in 30+ global life science financing transactions and advisory assignments and has led the team to close numerous deals. Before joining Yafo Capital, He was an equity research analyst covering the Chinese healthcare sector at Roth Capital Partners, a full-service investment banking firm headquartered in California. He was also a founder of a medical device start-up focusing on E.N.T related medical devices.
Mr. Yao Nengong graduated from Medical College of Shanghai JiaoTong University in 1990. After two years of being an OB doctor, Mr. Yao entered into the medical care industry in China. Before he joined in Yafo capital, he worked 7 years (1993-2000) in Astra China, the predecessor of AstraZeneca China, and oversaw government affair, marketing and BD in China. Also he has co-established the Cyberpharm Investment Co., Ltd. and Sino-Octa Holdings Limited, focusing on the medical care field in China. He is responsible for the Sales and Marketing and BD in the company.
Mr. Wang has rich experience in pharma Business Development for more than 20 years with a record of more than 50 M&A and licensing transactions. He has worked in Saiya Consulting, Eisai Pharma, Leo Pharma, and Yiteng Pharma. He served as the head of the BD department at Hemony Pharmaceuticals. He has accumulated a wealth of theoretical knowledge and practical experience in BD strategy, project commercial launching, project negotiations, investment and M&As, and alliance management.
Mr. Ye has more than 25+ years’ experience in Pharmaceutical industry, including the supply Chain as well as commercial and Business development. He served as Head of Business Development and Alliance Management in GSK China and was a member of GSK China Leadership Team. He also had 15years in Manufacturing in pharmaceutical industry. He was the Engineering and project manager for GE Healthcare Shanghai Plant, was a member of Plant Management Team. He also worked for Schering-Plough and Shanghai Number 6 pharmaceutical company for various positions.
Mr. Cai has more than 20 years experience in investment banking. He had working and project experience with multiple security companies including XIANGCAI Securities, SouthWest Securities, Soochow Securities, KAIYUAN Securities. He led the acquisition between Baihe Network and Jiayuan,com., two leading match-making websites in China. Other projects he led are: refinance of Zhangjiagang Freetrade Science & Technology Group, IPO of Bank of Nanjing, and issuing the ABS of Sound Group etc.
Mr. Mao is a venture partner of Yafo Capital. He has over 12 years experience in investment banking and private equity across North America and Asia.
He has led over $1.2 billion investments with leading financial institutions, such as Zhongzhi Enterprise Group, Sanpower Group, and Foundry Commercial. He offers unique insights in technology collaboration and cross border transactions.
Managing Director Israel
Rob creates new businesses in Japan that address the unmet needs of patients, doctors, innovators and authorities. He has three decades of focus on Japan’s healthcare ecosystem, deep regulatory knowledge and strong Key Opinion Leader doctor networks. Rob is passionate about developing innovative solutions for access to Japan’s healthcare market.
Rob is the founder of Junicon, a global healthcare consultancy, and Vorpal Technologies, a MedTech regulatory consultancy. He maintains a worldwide trust network with leading innovators in pharmaceuticals, MedTech and cellular therapies through optimism, tenacious follow-through and a spirit of collaboration.
Ben has two decades of experience in strategy development, marketing, and operations, and has commercialized and marketed best-in-class medical products globally and in Japan. As GM at Vorpal Technologies, he consulted overseas healthcare innovators and launched Vorpal Women’s Health, a Vorpal commercial entity sold in 2017. His forte and personal mission is creating new businesses for the betterment of patient care. Ben holds an MBA from the University of Southern California.
Russ has over two decades of business experience in Japan, and 16 years’ experience leading marketing, sales and clinical research functions for cardiovascular and neuromodulation businesses at Medtronic with Japan and Asia Pacific responsibilities.
Russ maintains strong relationships with thought leaders in many areas of cardiovascular medicine. He holds an MBA from the University of Michigan.
Hitoshi has 30 years of leadership experience in the life science industry including both large and venture biotech and pharmaceutical companies in executive management, finance, business development, and commercial roles.
Hitoshi’s background as a research scientist and financial professional make him a hands-on manager in biotech startups. He is experienced in private equity fundraising and IPO preparation and holds MBA & USCPA qualifications.
Anne is the former head of Medical Affairs, Clinical Development and Operations at Baxalta and Baxter Japan and was Medical Director for programs at Wyeth Japan and Eli Lilly Japan. Anne is a psychiatry medical doctor and has a track record of leading successful regulatory and clinical programs in oncology, CNS, hemophilia and anesthesia. Anne has been a resident of Japan for 19 years.
President and Representative Director, ARC Institution
• 20 years experience in the global medical device industry.
• Specialist in Interventional Cardiology and Interventional Peripheral Vascular businesses.
Entrepreneur & Investment Banker
• 20+ years of Japanese and American pharmaceutical industry experience, brioght over dozen US pharmaceutical products to the Japanese market
• President, Shire, Tokyo, 2012
• President, Solasia Pharma, Tokyo& China, 2007
Founding Partner, Cross Border
• Completed more than 50 European transactions
• Founder, Cross Border Biosalus – UK, 2018
• General Manager, Ciba Vision-Novartis, 1983
Managing Partner, Boler Biotech Consulting
• 20+ years biotechnology and pharmaceutical industry experience
• Strong research credentials in molecular biology, immunology & bioinformatics
• Former Research Scientist in Cell Biology